Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 0.59 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.59 |
| ▸ | GRM3 | Q14832 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | GRM6 | O15303 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | GRM8 | O00222 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GRM5 | P41594 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.59 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904567 | 0.88 | GRM4 (0.50) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL26923301 | 0.88 | GRM4 (0.50) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL26923345 | 0.88 | GRM4 (0.50) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL8179890 | 0.86 | GRM4 (0.52) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2906281 | 0.86 | GRM4 (0.52) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL14372097 | 0.86 | GRM4 (0.52) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL25393736 | 0.86 | ARG1 (0.49) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL31415483 | 0.86 | GRM4 (0.48) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL31415421 | 0.86 | GRM4 (0.48) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL26923446 | 0.86 | ARG1 (0.49) | GRM4GRM2GRM3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Oxford Drug Design Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-114846000-B | 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof | 牛津药物设计有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2023-04-13 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4077289-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| CN-114846000-A | 2-amino-N- (amino-oxo-aryl- λ 6-thioalkyl) acetamide compounds and therapeutic uses thereof | 牛津药物设计有限公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2021123237-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021123237-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| US-8269046-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY, LLC (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1631633-B1 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | ARIZONA CHEM (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100064933-A1 | Cyclic Bisamides Useful in Formulating Inks for Phase-Change Printing | ARIZONA CHEMICAL COMPANY LLC | 2010-03-18 | — | — | US | disclosed |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1631633-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | Arizona Chemical Company (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6960248-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2004106442-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | ARIZONA CHEMICAL COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040231555-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | AARS1, ASNS, GARS1 | GRM4 3597/4885GRM2 2104/4885GRM3 2260/4885 |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | AARS1, ASNS, GARS1 | GRM4 3597/4885GRM2 2104/4885GRM3 2260/4885 |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | FHIT, DDC, MNAT1 | GRM4 1563/4885GRM2 1395/4885GRM3 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.